Glasziou P P
NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia.
J Clin Epidemiol. 1992 Nov;45(11):1251-6. doi: 10.1016/0895-4356(92)90166-k.
Randomized controlled trials are usually analysed by the group to which the patient was randomized, i.e. by "intention-to-treat", regardless of the degree of compliance. However, the "explanatory" effect, i.e. the effect that would occur if we had 100% compliance, is often of interest. This "explanatory" effect is diluted by poor compliance, and hence meta-analyses should ideally avoid both the heterogeneity of effect due to variation in compliance rates among studies, and the undeserved weight given to trials with poor compliance. Newcombe's deattenuation method, which adjusts estimates for the degree of compliance, is extended and applied to a meta-analysis of the five reported randomized controlled trials of mammographic screening. Compliance with screening varied across studies: from 61 to 93% assigned to screening had one or more mammograms. The adjusted estimate of the reduction in breast cancer mortality at 9 years follow-up is 0.37 (95% confidence interval: 0.21, 0.49).
随机对照试验通常按患者随机分配至的组进行分析,即按“意向性治疗”分析,而不考虑依从程度。然而,“解释性”效应,即如果我们有100%的依从性时会出现的效应,通常是人们感兴趣的。这种“解释性”效应会因依从性差而被稀释,因此荟萃分析理想情况下应避免因各研究依从率不同导致的效应异质性,以及给予依从性差的试验不应有的权重。纽科姆的去衰减方法,该方法会根据依从程度调整估计值,已得到扩展并应用于对五项已报道的乳腺钼靶筛查随机对照试验的荟萃分析。各研究的筛查依从性各不相同:分配至筛查组的患者中,有61%至93%进行了一次或多次乳腺钼靶检查。在9年随访时,调整后的乳腺癌死亡率降低估计值为0.37(95%置信区间:0.21,0.49)。